Takeda Pharmaceutical Company Limited SEC filings document its reporting as a foreign private issuer and ADR-listed pharmaceutical company that furnishes Form 6-K current reports and files annual reports on Form 20-F. The filings include English-language earnings reports, financial appendices, press releases and governance notices.
Takeda’s regulatory disclosures cover IFRS consolidated results, outlook commentary, ADR and foreign-issuer reporting status, board and representative-director matters, corporate transformation initiatives, and clinical or regulatory updates for programs such as zasocitinib, rusfertide and oveporexton. The filings also document pipeline-related financial-impact statements, shareholder meeting materials and formal exhibits furnished to the SEC.
Takeda Pharmaceutical executive Rhonda Janice Pacheco, President of the U.S. Business Unit, filed an initial statement of ownership showing holdings of 149,252 American Depositary Shares. This amount represents an award of restricted stock units, each convertible into one ADS, subject to a multi-year vesting schedule.
The RSUs vest in three equal time-based tranches: 49,750 shares on July 1, 2026, 49,750 shares on July 1, 2027, and 49,752 shares on July 1, 2028. All shares are reported as directly owned, reflecting a significant equity-based compensation grant that aligns the executive’s interests with long-term company performance.
Takeda Pharmaceutical Co Ltd director Michel Bruno Orsinger has filed an initial ownership report detailing his equity interests in the company. The filing lists direct holdings of 7,600 American Depositary Shares and 9,700 Ordinary Shares. It also shows several equity-based awards, including Tax Obligation Awards economically equivalent to 1,152, 1,192 and 1,180 Ordinary Shares, scheduled to vest on different future dates. A cash-settled retirement award is tied to 6,532 Ordinary Shares. Footnotes describe additional restricted stock unit grants that convert into Ordinary Shares or cash upon vesting, with specified vesting dates and retirement-based vesting conditions.
Takeda Pharmaceutical Global Quality Officer Shannon Elaine Mary reported beneficial ownership of 57,580 American Depositary Shares. This filing is an initial ownership report, not a new buy or sell transaction.
The holding includes 27,146 restricted stock units, each equal to one ADS, vesting in tranches on July 1, 2026 (13,144 shares), July 1, 2027 (8,796 shares) and July 1, 2028 (5,206 shares).
Takeda Pharmaceutical director Jean Luc Butel filed an initial ownership report showing his current equity-related interests in the company. He holds 7,600 American Depositary Shares and 9,700 Ordinary Shares directly. The filing also lists several incentive awards tied to Takeda’s stock.
These include Tax Obligation Awards economically equivalent to 1,152, 1,192, and 1,180 Ordinary Shares, each with a 0 exercise price and expirations in 2026, 2027, and 2028, which will be settled in cash mainly to cover tax obligations. A Cash Settled Retirement Award references 6,532 Ordinary Shares and pays cash equal to share value when the director retires. Footnotes describe additional restricted stock units that convert into Ordinary Shares and then ADS upon vesting on June 1, 2026, 2027, and 2028.
TAKEDA PHARMACEUTICAL CO LTD director Miki Tsusaka has reported initial equity interests in the company. The filing shows direct ownership of 6,400 Ordinary Shares. It also lists restricted stock units that vest in tranches of 2,100 shares on June 1, 2026, 2,200 shares on June 1, 2027 and 2,100 shares on June 1, 2028. In addition, the report includes Tax Obligation Awards that are each economically equivalent to one Ordinary Share and are designed to be settled in cash at future vesting dates primarily to cover tax obligations.
Takeda Pharmaceutical’s Chief Financial Officer Furuta Milano has filed an initial ownership report showing existing equity interests. The filing lists direct ownership of 50,100 Ordinary Shares, including 19,500 restricted stock units (RSUs).
The RSUs represent a contingent right to receive one Ordinary Share each, vesting on June 1, 2026 (8,400 shares), June 1, 2027 (7,100 shares) and June 1, 2028 (4,000 shares). The report also shows several Tax Obligation Awards, each economically equivalent to one Ordinary Share, that upon vest will be settled in cash primarily to cover tax obligations at the then-current market price, rather than delivering shares. These entries reflect reported holdings rather than open‑market buying or selling.
Takeda Pharmaceutical’s President and CEO Christophe Weber has reported his initial ownership position on a Form 3. The filing lists direct holdings of 935,300 Ordinary Shares and 253,433 American Depositary Shares, plus various equity-based awards tied to future vesting dates.
The position includes 96,000 restricted stock units (RSUs) linked to Ordinary Shares, vesting on June 1, 2026 (46,100 shares), June 1, 2027 (32,700 shares) and June 1, 2028 (17,200 shares. It also includes 204,008 RSUs linked to American Depositary Shares, vesting on July 1, 2026 (95,744 shares), July 1, 2027 (72,384 shares) and July 1, 2028 (35,850 shares).
Weber also holds Tax Obligation Awards that are economically equivalent to Ordinary Shares, with underlying amounts of 46,367, 32,966 and 17,296 Ordinary Shares, expiring on June 1, 2026, June 1, 2027 and June 1, 2028. Upon vesting, these Tax Obligation Awards convert into cash payments primarily to cover tax obligations based on the then-current Ordinary Share price.
Takeda Pharmaceutical director John Maraganore reports his equity interests in the company. He shows direct holdings of 7,600 American Depositary Shares and 9,700 Ordinary Shares, along with Tax Obligation Awards that are economically equivalent to 1,152, 1,192 and 1,180 Ordinary Shares.
The filing also describes restricted stock unit awards that each convert into one Ordinary Share and then into an equivalent number of American Depositary Shares. These RSUs vest in tranches of 3,100, 3,400 and 3,200 shares on June 1, 2026, June 1, 2027 and June 1, 2028, respectively.
Takeda Pharmaceutical executive Giles Richard Platford, President of PDT, filed an initial ownership report showing beneficial ownership of 225,239 American Depositary Shares. This total includes 94,620 restricted stock units, each representing a contingent right to receive one American Depositary Share.
The restricted stock units vest over three dates: 44,638 shares on July 1, 2026, 32,396 shares on July 1, 2027, and 17,586 shares on July 1, 2028. These awards reflect equity-based compensation that will convert into shares only as they vest over time.
TAKEDA PHARMACEUTICAL CO LTD director Ian T. Clark filed an initial ownership report showing his existing equity interests in the company. The filing lists direct holdings of 9,696 American Depositary Shares and 9,700 Ordinary Shares, along with several equity-based awards.
These include "Tax Obligation Awards" economically equivalent to Ordinary Shares that will be settled in cash primarily to cover tax obligations, and a cash-settled retirement RSU award tied to the value of 2,356 Ordinary Shares. Additional RSU grants are scheduled to vest in tranches on June 1, 2026, June 1, 2027 and June 1, 2028, with each unit linked to one Ordinary Share and converting into American Depositary Shares upon vesting.